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Objective: An animal model of chronic severe heart failure is needed to evaluate
new mechanical devices, surgical procedures, and medical therapies. The purpose
of this study was to evaluate a unique new model of severe heart failure developed
by means of a novel protocol of rapid ventricular pacing.
Methods: Heart failure was induced in 8 mongrel dogs by means of rapid ventricu-
lar pacing (230 beats/min) for 4 weeks. After a sham operation, maintenance pac-
ing at a reduced rate (190 beats/min) was continued for another 4 weeks.
Results: Left ventricular systolic function was significantly reduced at week 4 and
remained low at week 8, including the slope of the end-systolic pressure-volume
relationship (2.4 ± 1.0 vs 0.7 ± 0.2 vs 0.8 ± 0.3 mm Hg/mL [baseline vs week 4 vs
week 8, respectively]), ejection fraction (63% ± 5% vs 28% ± 7% vs 33% ± 5%),
and cardiac output (3.1 ± 0.7 vs 2.0 ± 0.3 vs 2.2 ± 0.7 L/min). Significant ventric-
ular remodeling changes took place with increased ventricular volumes and cir-
cumferential wall stress, which were stable between weeks 4 and 8. Serum
catecholamine and atrial natriuretic polypeptide levels also increased from baseline
but stabilized between weeks 4 and 8. The end-diastolic pressure-volume relation-
ship also showed stable diastolic function between weeks 4 and 8.
Conclusions: Induction pacing at 230 beats/min readily created severe heart failure
in all animals, and a new technique of maintenance pacing provided a consistent
model of severe heart failure. This model can be used to study a variety of new
interventions for heart failure.
The epidemic of heart failure has led to the introduction of many newtherapies that work through a variety of mechanisms. However, it isdifficult to evaluate the long-term efficacy of these interventionsbecause of the lack of a suitable model of stable chronic dilated car-diomyopathy (DCM). The rapid-pacing heart-failure model has beenused to simulate DCM.1-6 However, after cessation of rapid ventric-
ular pacing, heart function quickly recovers.5,6 Modified pacing protocols have
been introduced7,8 to try to produce chronic DCM. However, 4 weeks after cessa-
tion of pacing, cardiac filling pressures and diastolic function returned to normal,
despite left ventricular (LV) systolic dysfunction.7 In another report with a long
induction period of pacing,8 8 to 22 weeks after cessation of pacing, LV end-dias-
tolic pressure (LVEDP) returned to normal, and there was significantly improved
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diastolic function. Therefore, even with these modified pro-
tocols designed to produce prolonged cardiac dysfunction,
it would be very difficult to determine whether an interven-
tion led to changes or whether the changes were due to
recovery after pacing cessation.
We hypothesized that after induction pacing with rapid
ventricular pacing (230 beats/min), chronic maintenance
pacing at a reduced rate (190 beats/min) would maintain a
stable level of severe cardiomyopathy similar to that of
patients with late-stage DCM. The purpose of this study
was to evaluate this unique model of chronic severe car-
diomyopathy by using numerous assessments, including
hemodynamic monitoring, 2-dimensional (2D) and 3-
dimensional (3D) echocardiography, pressure-volume loop
analyses, pathologic examination, LV mass and wall-stress
measurements, and neurohormone and serum cate-
cholamine measurements.
Materials and Methods
Animal Preparation and Surgical Procedures
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press (revised
1996). A total of 8 mongrel dogs (body weight, 26.6 ± 1.2 kg)
were anesthetized with intravenous thiopental (15 mg/kg) and
isoflurane (0.5%-2.5%). A conductance catheter with 2 Millar
pressure sensors (model SPC-562; Millar Instruments, Inc,
Houston, Tex) was inserted into the left ventricle. A thermistor-
tipped balloon catheter was inserted into the pulmonary artery. An
inferior vena cava occlusion catheter (SciMed Owens balloon
dilatation catheter; SciMed Life Systems, Inc, Maple Grove,
Minn) was inserted to obtain the LV pressure-volume loops under
various preloads. All hemodynamic data were recorded digitally
during steady state and inferior vena caval occlusion at a sample
rate of 200 Hz with the PowerLab (AD Instruments Inc, Mountain
View, Calif) data-acquisition system as baseline values. Cardiac
output was measured by using the thermodilution method. Stroke
volume was calculated from cardiac output and heart rate (HR). A
bipolar, screw-in, transvenous pacing lead (Medtronic 4068;
Medtronic Inc, Minneapolis, Minn) was inserted into the right
ventricular apex and attached to a programmable pulse generator
(Medtronic 8086; Medtronic Inc) placed into the cervical pocket.
Angiography was performed for LV volume calculation.
Rapid ventricular pacing (230 beats/min) was started 2 days or
more after the operation. Before pacing and on the 27th day of
pacing, 2D transthoracic echocardiography (TTE) studies were
performed with the animal awake and the pacemaker off. After 28
days of pacing at 230 beats/min, the animal was anesthetized in
the same way as in the previous study with the pacemaker off. The
hemodynamics were recorded as week 4 values in the same fash-
ion as for baseline values. A 3D TTE study with a matrix phased-
array volumetric 3D imaging system (System V3.01; Volumetrics
Medical Imaging, Durham, NC) was performed for the calibration
of conductance LV volumes. A median sternotomy was per-
formed, and the chest was opened. We waited for 45 minutes, sim-
ulating the time needed for cardiac interventions, and closed the
chest. Maintenance pacing at 190 beats/min was started on the
third postoperative day. Each animal was given furosemide (40
mg/d) postoperatively and placed under careful observation for
signs or symptoms of congestive heart failure for 4 weeks. Follow-
up 2D TTE studies were performed once a week.
On the 28th postoperative day, the animal was anesthetized in
the same way as for previous studies. The hemodynamics were
recorded as week 8 values in the same fashion as for baseline val-
ues. A 3D TTE study was performed. The animal was then killed.
The heart was harvested to measure the LV weight after trimming
off the right ventricular free wall and the atria7 and stored in 10%
formalin solution.
Additional studies were performed with 4 mongrel dogs (body
weight, 26.1 ± 0.4 kg) in which we acquired blood samples at
baseline and weeks 4, 5, 6, 7, and 8 for serum atrial natriuretic
polypeptide (ANP) and total catecholamine (norepinephrine, epi-
nephrine, and dopamine) measurements to better understand
changes in the maintenance period. The experimental protocol was
identical to that of our original 8 animals, except no hemodynamic
or echocardiographic data were obtained.
Hemodynamic Data Analysis
Data analysis was performed with a custom-made visual basic
program on Excel software (Excel 97 SR-1; Microsoft
Corporation, Redmond, Wash). The maximum and minimum rates
of change of LV pressure (LV dP/dtmax and LV dP/dtmin) were
determined as the first derivative of the LV pressure (LVP). The
time constant of isovolemic LVP decay (τ) was calculated by non-
linear regression.9
Pressure-Volume Loops
In 7 animals conductance volume data were acquired. LV volumes
measured with the conductance catheter were calibrated to a 3D TTE
or LV angiogram by a 2-point calibration on the basis of matching
end-diastolic (VED) and end-systolic (VES) volumes.10 The volume
from angiography was calculated by using the area-length method.11
The LV pressure-volume loops under various preloads were obtained
by occluding the inferior vena cava. By connecting the upper left cor-
ners of the pressure-volume loops with an iterative linear regression
method, we obtained the slope (Emax) of the end-systolic pressure-
volume relationship (ESPVR). The Emax is known to be a load-
independent index of LV contractility.12,13 We also evaluated the
slopes of the LV dP/dtmax-VED (dE/dt) and stroke work-VED (preload
recruitable stroke work) relationships, which are known to be load-
independent indices of LV contractility.14
The total energy generated by the left ventricle is approximated
as the pressure-volume area, which is circumscribed by the
ESPVR, end-diastolic pressure-volume relationship (EDPVR),
and the systolic trajectory of the pressure-volume loop. The area
inside the pressure-volume loop expresses external work. The ratio
of external work/pressure-volume area reflects the mechanical
efficiency of the ventricle.15
LV compliance, or diastolic property, was assessed by means
of the EDPVR during inferior vena caval occlusion. LVEDP and
LV volumes were fitted to the following exponential equation:
LVEDP = α × eβ × VED
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in each animal.16 We arbitrarily entered LVEDP values of 5, 10,
15, and 20 mm Hg in this equation and calculated corresponding
VED. These VED values were averaged and used to reconstruct the
EDPVR at each data point. One animal was excluded from this
analysis because the quality of data was not good enough to eval-
uate EDPVR.
Echocardiographic Parameters
End-diastolic and end-systolic cross-sectional areas (in square
centimeters) in the short-axis view, both at the mitral anulus level
(MAED and MAES) and at the midpapillary level (PAED and PAES),
and LV length (in centimeters), both end diastolic (LED) and end
systolic (LES), in the long-axis view were measured. VED (in mil-
liliters), VES (in milliliters), and ejection fraction (%) were calcu-
lated with the equations shown below17:
VED (mL) =
LED/3 × (MAED + [MAED + PAED]/2 + PAED/3);
VES (mL) =
LES/3 × (MAES + [MAES + PAES]/2 + PAES/3); and
Ejection fraction (%) = (VED – VES)/VED × 100.
From the Doppler echocardiogram, we evaluated the grade (0-
4+) of mitral regurgitation (MR) and tricuspid regurgitation (TR)
from the 4-chamber view.18
Circumferential wall stress (WS) was calculated from the 2D
TTE short-axis view at the papillary muscle level in combination
with LVP by means of the following formula19:
WS (103 · dynes · cm–2) = 1.33 × LVP × LVID/2/PWT,
where LVID is LV internal diameter (in centimeters) and PWT is
posterior wall thickness (in centimeters). Wall stress was calcu-
lated at both end-diastole (EDWS) and end-systole (ESWS).
LV mass was estimated by 2D TTE with the following formula20:
LV mass (mL) =
(π[LVID/2 + PWT]2 – π[LVID/2]2) × LED.
In addition, the actual LV mass was measured and normalized by
body weight at autopsy (LV mass index [in grams per kilograms]).7
Histologic and Biochemical Examination
The LV tissue was dehydrated and embedded in paraffin. Serial sec-
tions were cut at a thickness of 5 µm and stained with hematoxylin
and eosin at American Histolabs (Gaithersburg, Md). All the histo-
logic examinations were done by an experienced pathologist.
Blood for plasma ANP and catecholamine assay was collected
in ethylenediamine tetraacetic acid and heparinized tubes, respec-
tively, and immediately placed on ice. After centrifugation at 3500
revolutions per minute for 7 minutes, the plasma was decanted and
stored at –20°C until analysis. Plasma ANP was measured by
means of specific radioimmunoassay (Mayo Medical Laboratories,
Rochester, Minn).21 Plasma catecholamine concentrations were
determined by high-performance liquid chromatography.
Statistical Analysis
All data were expressed as mean values ± SD. The changes of all
parameters from baseline to week 4, baseline to week 8, and week
4 to week 8 were analyzed with a paired t test. No correction of P
values for multiple comparisons was made. Changes in parameters
that have multiple data points (baseline and weeks 4, 5, 6, 7, and
8) were analyzed by repeated-measures analysis of variance for
those during the maintenance period (weeks 4-8) and with paired
t tests for those between baseline and weeks 4 to 8.
Results
The changes in basic hemodynamics are shown in Table 1.
Cardiac output, stroke volume, systolic LVP, LVEDP, LV
dP/dtmax, LV dP/dtmin, mean aortic pressure, and pulmonary
capillary wedge pressure were significantly worse at both
weeks 4 and 8 compared with baseline values. Although
most of the parameters were stable between weeks 4 and 8,
TABLE 1. Basic hemodynamics and echocardiography-
derived parameters (n = 8)
Condition Baseline Week 4 Week 8
CO (L/min) 3.1 ± 0.7 2.0 ± 0.3* 2.2 ± 0.7*
HR (beats/min) 125 ± 10 115 ± 19 140 ± 16*†
SV (mL) 25 ± 5 18 ± 4* 15 ± 4*
Systolic LVP (mm Hg) 135 ± 26 107 ± 14* 105 ± 21*
LVEDP (mm Hg) 7 ± 2 29 ± 10* 21 ± 12*†
LVdP/dtmax (mm Hg/s) 2135 ± 765 1114 ± 243* 1204 ± 374*
LVdP/dtmin (mm Hg/s) –3013 ± 1006 –1178 ± 261* –1558 ± 388*†
τ (ms) 33.1 ± 3.8 63.2 ± 7.8* 38.7 ± 8.4†
Mean AoP (mm Hg) 124 ± 20 95 ± 10* 93 ± 21*
SVR (dynes · s · m–5)‡ 3177 ± 510 3506 ± 478 3331 ± 880
Mean CVP (mm Hg) 3 ± 3 7 ± 4 6 ± 4*
Mean PCWP (mm Hg) 6 ± 2 22 ± 12* 16 ± 11*
Mean PAP (mm Hg) 13 ± 2 28 ± 13* 22 ± 12†
PVR (dynes · s · m–5)‡ 178 ± 47 263 ± 99* 231 ± 127
VED (mL) 79.2 ± 8.7 119.9 ± 18.4* 114.4 ± 26.5*
VES (mL) 29.3 ± 4.4 86.7 ± 19.6* 76.1 ± 18.3*
EF (%) 62.9 ± 5.2 28.4 ± 7.3* 33.4 ± 4.8*
MR (grade 0-4+) 0.1 ± 0.2 1.4 ± 0.9* 1.3 ± 1.1*
TR (grade 0-4+) 0.3 ± 0.3 1.9 ± 0.8* 1.8 ± 1.2*
ESWS (103 · dynes · cm–2) 230 ± 44 365 ± 46* 337 ± 79*
EDWS (103 · dynes · cm–2) 24 ± 6 123 ± 49* 85 ± 55*†
LV mass (mL) 100 ± 15 106 ± 20 112 ± 12
AoP, Aortic pressure; CO, cardiac output; CVP, central venous pressure;
EDWS, end-diastolic wall stress; EF, ejection fraction; ESWS, end-systolic
wall stress; HR, heart rate; LVdP/dtmax, maximum rate of change of LVP;
LVdP/dtmin, minimum rate of change of LVP; LVEDP, left ventricular end-
diastolic pressure; MR, mitral regurgitation; PAP, pulmonary arterial pres-
sure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary
vascular resistance; SV, stroke volume calculated from cardiac output
and heart rate; SVR, systemic vascular resistance; τ, time constant of iso-
volemic LVP decay; TR, tricuspid regurgitation; VED, end-diastolic volume;
VES, end-systolic volume.
*P < .05 compared with baseline.
†P < .05 compared with week 4.
‡SVR and PVR were calculated as follows: (mean AoP – CVP)/CO × 80 and
(mean PAP – PCWP)/CO × 80, respectively.
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some changed. HR significantly increased at week 8 com-
pared with baseline and week 4 values. LVEDP, LV
dP/dtmin, τ, and mean pulmonary arterial pressure signifi-
cantly decreased at week 8 compared with at week 4.
The changes in echocardiography-derived data are
shown in Table 1 and Figure 1. VED and VES significantly
increased, which is typical of a remodeled failing heart, and
ejection fraction significantly decreased at week 4 com-
pared with baseline values. These changes were maintained
and stable between weeks 4 and 8. None of the animals
showed evidence of MR or TR greater than trivial levels at
baseline. At week 4, significant MR and TR developed
compared with baseline values. Both of them remained at
week 8 and were unchanged (P = not significant) from
week 4. ESWS and EDWS significantly increased at weeks
4 and 8 compared with baseline values. Although ESWS
was stable between weeks 4 and 8 (P = not significant),
EDWS significantly decreased at week 8 compared with at
week 4. LV mass increased continuously from baseline to
week 8 and approached significance (P = .06). In addition,
LV mass index measured at autopsy was 5.36 ± 0.70 g/kg,
which was comparable with a previous report of canine
paced heart failure.7
Parameters from pressure-volume analysis are shown in
Table 2. Emax (P = .004), preload recruitable stroke work (P
= .03), and dE/dt (P = .02) significantly decreased at week
4 compared with baseline values. These changes were
maintained at week 8 (P = .009, P = .02, and P = .03 vs
baseline values, respectively; all P = not significant vs week
4 values). The volume axis intercept of ESPVR was –15 ±
19 mL at baseline, –100 ± 65 mL at week 4, and –90 ± 70
mL at week 8. The volume axis intercept of the stroke work-
VED relationship was 16 ± 18 mL at baseline, –18 ± 59 mL
at week 4, and –2 ± 48 mL at week 8. LV efficiency signif-
icantly decreased at week 4 (P = .01 vs baseline values) and
was stable at week 8 (P = not significant vs week 4 values).
In addition, the evaluation of reconstructed EDPVR at
LVEDP values of 5, 10, 15, and 20 mm Hg revealed that all
these points were not significantly different at week 8 com-
pared with week 4 values (P = not significant).
Hypertrophy of cardiac myofibers, which is characterized
by large, rounded, eosinophilic cells with a large and promi-
nent basophilic nucleus, and interstitial edema were com-
mon in the myocardium of all animals. The apical side of the
septum usually demonstrated the most marked hypertrophy.
Plasma ANP and total catecholamine levels were signif-
icantly increased at week 4 compared with baseline values
and remained elevated and stable between weeks 4 and 8, as
Figure 1. VED, VES, and ejection fraction (EF) from echocardiogra-
phy (n = 8). VED significantly (P = .0003) increased at week 4 com-
pared with baseline values. VES also significantly (P = .0001)
increased at week 4 compared with baseline values.
Consequently, ejection fraction significantly (P = .000003)
decreased at week 4. These changes were maintained at week 8
(P = .005, P = .0001, and P = .000001 vs baseline values, respec-
tively; all P = not significant vs week 4). The changes of parame-
ters between weeks 4 and 8 and from baseline to each week were
analyzed with repeated-measures analysis of variance and a
paired t test. Analysis of variance showed no significant changes
in these echocardiographic parameters between weeks 4 and 8.
*P < .05 compared with baseline values.
Figure 2. Plasma biochemical markers (n = 4). ANP and total cat-
echolamine (norepinephrine, epinephrine, and dopamine) levels
were significantly (P < .05) increased at week 4 (301 ± 117 and
1599 ± 333 pg/mL) compared with baseline levels (53 ± 20 and 545
± 128 pg/mL) and remained elevated between weeks 4 and 8. The
changes of parameters between weeks 4 and 8 and from baseline
to each week were analyzed with repeated-measures analysis of
variance and a paired t test. Analysis of variance showed no sig-
nificant changes in these biochemical parameters between
weeks 4 and 8. *P < .05 compared with baseline levels.
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shown in Figure 2. Analysis of variance showed no signifi-
cant changes between weeks 4 and 8.
Discussion
Consistent with previous investigations, we were able to use
induction pacing to create severe LV dysfunction, and heart
failure was manifested by changes in all parameters. Unlike
previous studies, however, the maintenance pacing at 190
beats/min allowed a very stable model of severe cardiomyopa-
thy to emerge. Measurements of pressure-volume loops,
hemodynamics, echocardiography, LV mass and wall stress,
pathologic examination, and plasma ANP and catecholamine
levels all confirmed severe, persistent cardiomyopathy. The
model was associated with structural changes consistent with
LV remodeling, reduction in LV performance measured by
means of load-independent methods, elevated levels of plasma
ANP and catecholamines, and impaired hemodynamics.
Furthermore, the dilated, poorly contracting hearts exhibited
MR and TR at a level that is common in patients with DCM.
Although the majority of parameters were stable
between weeks 4 and 8, not all measurements remained sta-
ble. There was an increase in HR at week 8 compared with
at week 4, and LVEDP, LV dP/dtmin, τ, mean pulmonary
arterial pressure, and EDWS significantly decreased at
week 8 compared with week 4 values. These values, how-
ever, were still distinctly abnormal compared with baseline
values. The use of furosemide between weeks 4 and 8 may
have accounted for some of the decrease in cardiac filling
pressures and led to the compensatory increase in HR to
maintain cardiac output. Our prior studies22 indicated that
maintaining animals at this level of heart failure without
furosemide led to a high mortality caused by chronic vol-
ume overload with pleural effusions and ascites. Although
the increased HR may have influenced the HR-dependent
parameters, such as τ and LV dP/dtmin, it is more likely that
measures of active relaxation improved significantly from
week 4. However, our observation that EDPVR did not
change between weeks 4 and 8 implied that passive dia-
stolic properties did not change in this model.
Other investigators have achieved a chronic model of
heart failure through the use of coronary microsphere injec-
tions.23,24 The microsphere-damaged myocardium model
exhibits extensive fibrosis and is more akin to ischemic car-
diomyopathy than DCM. Also, unlike the microsphere-
injection model, which may require multiple procedures
and several months to induce heart failure, this pacing-
induced heart-failure model can be initiated with a single
operation, the pacemaker implantation.
Although previous models of pacing-induced heart fail-
ure demonstrated recovery of cardiac function after cessa-
tion of pacing, even with modified protocols,7,8 our model
maintained a much more severe cardiomyopathy and there-
fore was clinically similar to patients with end-stage car-
diomyopathy. In one earlier study,8 ejection fraction
recovered from 25% to 45% 2 weeks after the cessation of
pacing, and LVEDP decreased from 15 to 5 mm Hg 8 weeks
after cessation of pacing. In our model there was a persis-
tently depressed myocardial performance.
Much attention is being directed to finding new therapies
for heart failure. New surgical or device-based therapies
that may be addressed by this model include the Myocor
Myosplint,22 Acorn Cardiac Support Device,25
Cardioclasp,26 Batista procedure (partial left ventriculec-
tomy),27 mitral valve repair for severe LV dysfunction,28
gene therapy,29 or cell therapy.30 Although the chronic
microembolization model may be applicable to some of
these innovations, a model more closely approximating
idiopathic DCM would be useful.
Study Limitation
Although the majority of parameters were stable between
weeks 4 and 8, some cardiac filling pressures decreased.
HR increased, perhaps associated with the furosemide
administered to maintain the animals at clinically stable lev-
els, allowing them to survive to study termination. MR in
this model was evaluated with color Doppler scanning, and
more quantitative evaluation, including assessment of prox-
imal isovelocity surface area, would be more appropriate
for further studies. Furthermore, because MR is an impor-
tant component of DCM, another protocol to create more
severe MR may be appropriate to assess interventions on
the mitral valve. Although LV mass increased continuously
from baseline to week 8, it did not reach statistical signifi-
cance (P = .06). Lack of hypertrophy in this model should
be considered as a limitation. Because the volume axis
intercept for ESPVR was much smaller after induction of
heart failure, there might have been some problems with
absolute values of volumes. However, this calibration
method by matching VES and VED is the only theoretically
reasonable method in the presence of MR, unless we can
measure the amount of MR precisely. Although it was
impossible to validate this calibration in our data, the simi-
TABLE 2. Results of pressure-volume loops analysis (n = 7)
Condition Baseline Week 4 Week 8
Emax (mm Hg/mL) 2.4 ± 1.0 0.7 ± 0.2* 0.8 ± 0.3*
PRSW (mm Hg) 49.5 ± 28.3 26.4 ± 16.5* 19.2 ± 5.5*
dE/dt (mm Hg · s–1 · mL–1) 19.4 ± 11.6 5.3 ± 2.9* 7.0 ± 3.7*
LV efficiency (%) 39 ± 12 23 ± 9* 18 ± 7*
Emax, Slope of end-systolic pressure-volume relationship; dE/dt, slope of
the LV dP/dtmax-VED relationship; LV dP/dtmax, maximum rate of change of
LV pressure; PRSW, Preload recruitable stroke work (slope of the stroke
work-VED relationship).
*P < .05 compared with baseline.
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lar changes in much simpler parameters, such as LV
dP/dtmax, support our conclusion of depressed contractility
at weeks 4 and 8. Finally, these studies were designed to ter-
minate at week 8, and it is not yet known how much longer
animals can be maintained in this late stage of heart failure.
Conclusion
Induction pacing at 230 beats/min over 4 weeks produced
severe cardiomyopathy in all animals. Maintenance pacing
at 190 beats/min maintained a stable level of severe
cardiomyopathy similar to that of patients with end-stage
idiopathic DCM. This model of persistent, severe cardio-
myopathy should allow for the evaluation of new and exist-
ing therapies for heart failure.
We thank Dr George Ruth for his pathologic examinations and
Mr Michael Kopcak for his excellent technical assistance in the
experiments. We also thank Ms Christine Kassuba for editorial
assistance in the preparation of this article.
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